This board had great luck with its initial jump into biotech. However NKTR’s path is far more common with biotechs. I do not know what news, but down it has gone again today on some bit of news or other.
To be very honest, I’m surprised that Nektar Therapeutics gets the most modest notes of notes.
The company, over thirty years in the making, currently losing money at an accelerated rate (YOY), had a ‘major’ flash in the pan stock price run up ten months ago… unsustained…
May be a buy in the future, just not now…